Amsterdam, Netherlands – Nicolab, a distinguished pioneer in stroke workflow technology, is thrilled to announce a strategic partnership with Veritas Biomedical, a leading Taiwanese provider of innovative medical technologies and devices. This collaboration will enhance stroke care in Taiwan by delivering Nicolab’s state-of-the-art AI solutions to healthcare providers.
Nicolab’s flagship product, StrokeViewer, will be offered through Veritas’s extensive network, providing healthcare facilities across the region with cutting-edge AI-powered stroke care solutions. StrokeViewer utilises advanced AI algorithms to provide clinicians with quick, reliable, and vital information, enabling well-informed treatment decisions anywhere and anytime.
Stroke remains a leading cause of mortality and disability in Taiwan, with incidence rates rising due to factors like hypertension, diabetes, and smoking. This partnership addresses the urgent need for advanced stroke care solutions, particularly in the context of a rapidly aging population.
The National Health Insurance Administration (NHIA) in Taiwan has recently expanded the reimbursement criteria for thrombectomy from less than 8 hours to within 24 hours of stroke onset. Patients treated in the 8-24 hour window must have advanced imaging reports (CTP, MR, or CTA collaterals), underscoring the necessity for advanced stroke software like StrokeViewer.
Terry Lin, General Manager of Veritas Biomedical, expressed enthusiasm about the partnership: “In an era where technology is reshaping the landscape of healthcare, collaboration between industry leaders is paramount. Through our partnership with Nicolab, we aim to propel the Taiwan healthcare sector into a new era of innovation and efficiency. Nicolab’s AI solutions align seamlessly with our mission to optimise patient care through cutting-edge technology.”
Veritas Biomedical has key partnerships with companies such as SAM Medical, XVIVO, and Peli Biothermal and has already delivered solutions to hundreds of customers, optimising clinical workflow and improving overall efficiency. The partnership with Nicolab represents a commitment to driving innovation in healthcare. This strategic collaboration will enable healthcare facilities across Taiwan to harness the power of AI to improve diagnostic accuracy, optimise treatment planning, and ultimately enhance patient care.
About Nicolab
Nicolab, established in 2015 following the world-leading MR CLEAN clinical trial, is an Australian-based public unlisted company. Comprised of a team of esteemed researchers, developers, and medical specialists, Nicolab is dedicated to developing innovative healthcare solutions that improve patient care. Operating globally, Nicolab’s flagship product, StrokeViewer, enables clinicians to connect, communicate, and collaborate effectively within their stroke network, revolutionising stroke workflow and treatment planning.
For media inquiries, please contact:
